Pharmalink AB, a Sweden-based specialty pharmaceutical company, has raised SEK96 million (€11.1 million) in a Series C round to advance the clinical development of products to treat patients with cancer and renal disease. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
